• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Novel methods for tracking long-term maintenance immunosuppression regimens.追踪长期维持免疫抑制方案的新方法。
Clin J Am Soc Nephrol. 2008 Jan;3(1):117-24. doi: 10.2215/CJN.02790707. Epub 2007 Dec 12.
2
Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey.医疗保险药房理赔中描述的免疫抑制方案与器官获取与移植网络调查的一致性。
J Am Soc Nephrol. 2006 Aug;17(8):2299-306. doi: 10.1681/ASN.2006030258. Epub 2006 Jul 6.
3
Balancing efficacy and toxicity in kidney-transplant immunosuppression.肾移植免疫抑制中疗效与毒性的平衡
N Engl J Med. 2007 Dec 20;357(25):2625-7. doi: 10.1056/NEJMe078181.
4
Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.肾移植中新型免疫抑制方案的临床疗效与成本效益:一项系统评价与模型研究
Health Technol Assess. 2005 May;9(21):1-179, iii-iv. doi: 10.3310/hta9210.
5
Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.台湾肾移植受者使用维持性免疫抑制药物的趋势:基于国民健康保险研究数据库的分析
Transplant Proc. 2012 Jan;44(1):190-2. doi: 10.1016/j.transproceed.2011.12.018.
6
Improved outcome of pediatric kidney transplantations in the Netherlands -- effect of the introduction of mycophenolate mofetil?荷兰儿科肾移植预后的改善——霉酚酸酯引入的影响?
Pediatr Transplant. 2005 Feb;9(1):104-11. doi: 10.1111/j.1399-3046.2005.00271.x.
7
The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.西罗莫司、霉酚酸酯、环孢素、硫唑嘌呤和类固醇对513例肾移植受者伤口愈合的影响。
Transplantation. 2003 Dec 27;76(12):1729-34. doi: 10.1097/01.TP.0000093502.26208.42.
8
[Immunosuppression for kidney transplant recipients: current strategies].[肾移植受者的免疫抑制:当前策略]
Rev Invest Clin. 2005 Mar-Apr;57(2):213-24.
9
Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.肾移植采用西罗莫司和霉酚酸酯为基础的免疫抑制治疗:与钙调神经磷酸酶抑制剂药物相比的随机前瞻性试验5年结果
Transplantation. 2007 Apr 15;83(7):883-92. doi: 10.1097/01.tp.0000258586.52777.4c.
10
Optimizing the immunosuppressive regimen in heart transplantation.优化心脏移植中的免疫抑制方案。
J Heart Lung Transplant. 2004 May;23(5 Suppl):S207-13. doi: 10.1016/j.healun.2004.03.010.

引用本文的文献

1
Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes.肾移植后的血栓性微血管病:对遗传病因和临床结局的见解
Kidney Int Rep. 2025 Jan 30;10(4):1152-1162. doi: 10.1016/j.ekir.2025.01.026. eCollection 2025 Apr.
2
National Variation in Use of Immunosuppression for Kidney Transplantation: A Call for Evidence-Based Regimen Selection.肾移植免疫抑制使用的全国性差异:呼吁基于证据的方案选择。
Am J Transplant. 2016 Aug;16(8):2453-62. doi: 10.1111/ajt.13758. Epub 2016 Mar 31.
3
Cancer diagnoses after living kidney donation: linking U.S. Registry data and administrative claims.活体肾捐献后的癌症诊断:美国注册数据与行政索赔的关联。
Transplantation. 2012 Jul 27;94(2):139-44. doi: 10.1097/TP.0b013e318254757d.
4
Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry.成人对成人活体肝移植队列研究(A2ALL)与 SRTR 美国移植登记处的数据库比较。
Am J Transplant. 2010 Jul;10(7):1621-33. doi: 10.1111/j.1600-6143.2010.03039.x. Epub 2010 Feb 25.
5
Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients.肾移植受者心血管疾病事件计费索赔的敏感性。
Clin J Am Soc Nephrol. 2009 Jul;4(7):1213-21. doi: 10.2215/CJN.00670109. Epub 2009 Jun 18.
6
Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons.肾移植中胸腺球蛋白和巴利昔单抗诱导治疗的早期结果:应用统计学方法减少观察性比较中的偏倚
Transplantation. 2009 May 27;87(10):1520-9. doi: 10.1097/TP.0b013e3181a484d7.

本文引用的文献

1
Linking the US transplant registry to administrative claims data: expanding the potential of transplant research.将美国移植登记处与行政索赔数据相连接:拓展移植研究的潜力。
Med Care. 2007 Jun;45(6):529-36. doi: 10.1097/MLR.0b013e3180326121.
2
Differences between clinical trial efficacy and real-world effectiveness.临床试验疗效与真实世界有效性之间的差异。
Am J Manag Care. 2006 Nov;12(15 Suppl):S405-11.
3
Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey.医疗保险药房理赔中描述的免疫抑制方案与器官获取与移植网络调查的一致性。
J Am Soc Nephrol. 2006 Aug;17(8):2299-306. doi: 10.1681/ASN.2006030258. Epub 2006 Jul 6.
4
Quality of care in for-profit and not-for-profit health plans enrolling Medicare beneficiaries.参保医疗保险受益人的营利性和非营利性健康保险计划的医疗服务质量。
Am J Med. 2005 Dec;118(12):1392-400. doi: 10.1016/j.amjmed.2005.05.032.
5
Deceased-donor characteristics and the survival benefit of kidney transplantation.已故供体特征与肾移植的生存获益
JAMA. 2005 Dec 7;294(21):2726-33. doi: 10.1001/jama.294.21.2726.
6
Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.接受霉酚酸酯治疗的肾移植患者胃肠道并发症的长期转归
Transpl Int. 2004 Nov;17(10):609-16. doi: 10.1007/s00147-004-0768-6. Epub 2004 Oct 29.
7
Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study.肾移植受者免疫抑制剂治疗依从性的可改变危险因素:一项横断面研究。
Nephrol Dial Transplant. 2004 Dec;19(12):3144-9. doi: 10.1093/ndt/gfh505. Epub 2004 Oct 12.
8
Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.安大略省药物福利数据库中行政药物报销申请的编码准确性。
Can J Clin Pharmacol. 2003 Summer;10(2):67-71.
9
Medication lists for elderly patients: clinic-derived versus in-home inspection and interview.老年患者的用药清单:诊所获取与居家检查及访谈对比
J Gen Intern Med. 2001 Feb;16(2):112-5. doi: 10.1111/j.1525-1497.2001.00303.x.
10
Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels.为医疗保险受益人提供的医疗服务质量:州和国家层面的概况。
JAMA. 2000 Oct 4;284(13):1670-6. doi: 10.1001/jama.284.13.1670.

追踪长期维持免疫抑制方案的新方法。

Novel methods for tracking long-term maintenance immunosuppression regimens.

作者信息

Buchanan Paula M, Schnitzler Mark A, Brennan Daniel C, Dzebisashvili Nino, Willoughby Lisa M, Axelrod David, Salvalaggio Paolo R, Abbott Kevin C, Burroughs Thomas E, Lentine Krista L

机构信息

Center for Outcomes Research, St. Louis University School of Medicine, St. Louis, Missouri, USA.

出版信息

Clin J Am Soc Nephrol. 2008 Jan;3(1):117-24. doi: 10.2215/CJN.02790707. Epub 2007 Dec 12.

DOI:10.2215/CJN.02790707
PMID:18077785
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2390985/
Abstract

BACKGROUND AND OBJECTIVES

Accurate assessment of the use of immunosuppressive medications is vital for observational analyses that are widely used in transplantation research. This study assessed the accuracy of three potential sources of maintenance immunosuppression data.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study investigated the agreement of immunosuppression information in directly linked electronic medical records for Medicare beneficiaries who received a kidney transplant at one center in 1998 through 2001, Organ Procurement and Transplantation Network (OPTN) survey data, and Medicare pharmacy claims. Pair-wise, interdata concordance (kappa) and percentage agreement statistics were used to compare immunosuppression regimens reported at discharge, and at 6 mo and 1 yr after transplantation in each data source.

RESULTS

Among 181 eligible participants, agreement between data sources for nonsteroid immunosuppression increased with time after transplantation. By 1-yr, concordance was excellent for calcineurin inhibitors and mycophenolate mofetil (kappa = 0.79 to 1.00), and very good for azathioprine (kappa = 0.73 to 0.85). Similarly, percentage agreement at 1 yr was 94.9 to 100% for calcineurin inhibitors, 91.1 to 95.7% for mycophenolate mofetil, and 87.5 to 92.8% for azathioprine. Widening the comparison time window resolved 33.6% of cases with discordant indications of calcineurin inhibitor and/or antimetabolite use in claims compared with other data sources.

CONCLUSIONS

This analysis supports the accuracy of the three sources of data for description of nonsteroid immunosuppression after kidney transplantation. Given the current strategic focus on reducing collection of data, use of alternative measures of immunosuppression exposure is appropriate and will assume greater importance.

摘要

背景与目的

准确评估免疫抑制药物的使用情况对于移植研究中广泛使用的观察性分析至关重要。本研究评估了维持免疫抑制数据的三个潜在来源的准确性。

设计、地点、参与者与测量:本研究调查了1998年至2001年在一个中心接受肾移植的医疗保险受益人的直接关联电子病历、器官获取与移植网络(OPTN)调查数据以及医疗保险药房报销记录中的免疫抑制信息的一致性。采用两两数据间的一致性(kappa)和百分比一致性统计来比较各数据源中移植出院时、移植后6个月和1年报告的免疫抑制方案。

结果

在181名符合条件的参与者中,非甾体免疫抑制的数据来源之间的一致性随移植后时间增加。到1年时,钙调神经磷酸酶抑制剂和霉酚酸酯的一致性极佳(kappa = 0.79至1.00),硫唑嘌呤的一致性非常好(kappa = 0.73至0.85)。同样,1年时钙调神经磷酸酶抑制剂的百分比一致性为94.9%至100%,霉酚酸酯为91.1%至95.7%,硫唑嘌呤为87.5%至92.8%。与其他数据源相比,扩大比较时间窗口解决了33.6%的报销记录中钙调神经磷酸酶抑制剂和/或抗代谢物使用指征不一致的病例。

结论

该分析支持了这三个数据源用于描述肾移植后非甾体免疫抑制情况的准确性。鉴于当前对减少数据收集的战略重点,使用免疫抑制暴露的替代测量方法是合适的,并且将变得更加重要。